id stringlengths 9 11 | source stringclasses 1
value | title stringlengths 15 560 | text stringlengths 2k 153k |
|---|---|---|---|
PMC6736360 | core_pubmed_pmc | P-Glycoprotein–Mediated Efflux Reduces the In Vivo Efficacy of a Therapeutic Targeting the Gastrointestinal Parasite Cryptosporidium | P-Glycoprotein–Mediated Efflux Reduces the In Vivo Efficacy of a Therapeutic Targeting the Gastrointestinal Parasite Cryptosporidium Abstract Abstract Recent studies have illustrated the burden Cryptosporidium infection places on the lives of malnourished children and immunocompromised individuals. Treatment options re... |
PMC12173072 | core_pubmed_pmc | Preparation and pharmacokinetic evaluation of Staphylococcus phage COP-80B for treatment of periprosthetic joint infections in a mouse model | Preparation and pharmacokinetic evaluation of Staphylococcus phage COP-80B for treatment of periprosthetic joint infections in a mouse model Abstract Highlights • Rapid and scalable production method yields pharmaceutical-grade phage preparation. • Local phage administration results in sustained phage presence in the k... |
PMC12324812 | core_pubmed_pmc | Model‐Informed Paradigm in Drug Development—An End‐To‐End Case Study From Upadacitinib Development | Model‐Informed Paradigm in Drug Development—An End‐To‐End Case Study From Upadacitinib Development Abstract ABSTRACT Model‐informed drug development (MIDD) entails applying quantitative approaches to assist with decision‐making during drug development and has been used for dose optimization, to inform clinical trial de... |
PMC9525356 | core_pubmed_pmc | Risperidone ISM as a New Option in the Clinical Management of Schizophrenia: A Narrative Review | Risperidone ISM as a New Option in the Clinical Management of Schizophrenia: A Narrative Review Abstract Antipsychotics are the cornerstone of schizophrenia treatment. Lack of treatment adherence encouraged the development of injectable long-acting antipsychotics. However, second-generation or atypical antipsychotics r... |
PMC4972158 | core_pubmed_pmc | Impact of perampanel on pharmacokinetics of concomitant antiepileptics in patients with partial‐onset seizures: pooled analysis of clinical trials | Impact of perampanel on pharmacokinetics of concomitant antiepileptics in patients with partial‐onset seizures: pooled analysis of clinical trials Abstract Aims To evaluate the impact of perampanel and demographics on clearance of concomitant antiepileptic drugs (AEDs), in patients with refractory partial‐onset seizure... |
PMC4458577 | core_pubmed_pmc | Modeling transportation of efavirenz: inference on possibility of mixed modes of transportation and kinetic solubility | Modeling transportation of efavirenz: inference on possibility of mixed modes of transportation and kinetic solubility Abstract Understanding drug transportation mechanisms in the human body is of paramount importance in modeling Pharmacokinetic-Pharmacodynamic relationships. This work gives a novel general model of ef... |
PMC12115050 | core_pubmed_pmc | Harnessing the Power of Nanocarriers to Exploit the Tumor Microenvironment for Enhanced Cancer Therapy | Harnessing the Power of Nanocarriers to Exploit the Tumor Microenvironment for Enhanced Cancer Therapy Abstract Abstract The tumor microenvironment (TME) has a major role in malignancy and its complex nature can mediate tumor survival, metastasis, immune evasion, and drug resistance. Thus, reprogramming or regulating t... |
PMC11970287 | core_pubmed_pmc | Pharmacokinetic properties of once‐weekly insulin icodec in Chinese individuals with type 2 diabetes | Pharmacokinetic properties of once‐weekly insulin icodec in Chinese individuals with type 2 diabetes Abstract ABSTRACT Introduction Insulin icodec is a novel once‐weekly basal insulin developed for the treatment of diabetes. The aim of this study was to investigate the pharmacokinetics of icodec in Chinese individuals ... |
PMC3049593 | core_pubmed_pmc | PG545, a dual heparanase and angiogenesis inhibitor, induces potent anti-tumour and anti-metastatic efficacy in preclinical models | PG545, a dual heparanase and angiogenesis inhibitor, induces potent anti-tumour and anti-metastatic efficacy in preclinical models Abstract Abstract Background: PG545 is a heparan sulfate (HS) mimetic that inhibits tumour angiogenesis by sequestering angiogenic growth factors in the extracellular matrix (ECM), thus lim... |
PMC3162145 | core_pubmed_pmc | Pharmacokinetics of aprepitant and dexamethasone after administration of chemotherapeutic agents and effects of plasma substance P concentration on chemotherapy-induced nausea and vomiting in Japanese cancer patients | Pharmacokinetics of aprepitant and dexamethasone after administration of chemotherapeutic agents and effects of plasma substance P concentration on chemotherapy-induced nausea and vomiting in Japanese cancer patients Abstract Purpose This study was conducted to determine the pharmacokinetics of aprepitant and dexametha... |
PMC11179695 | core_pubmed_pmc | A population pharmacokinetic model using allometric scaling for baricitinib in patients with juvenile idiopathic arthritis | A population pharmacokinetic model using allometric scaling for baricitinib in patients with juvenile idiopathic arthritis Abstract Abstract Baricitinib is approved for the treatment of rheumatoid arthritis (RA) in more than 70 countries, and juvenile idiopathic arthritis (JIA) in the European Union. Population pharmac... |
PMC6155382 | core_pubmed_pmc | The Effects of Sweet Foods on the Pharmacokinetics of Glycyrrhizic Acid by icELISA | The Effects of Sweet Foods on the Pharmacokinetics of Glycyrrhizic Acid by icELISA Abstract Abstract The effect of sweet foods, such as honey, was investigated from the perspective of pharmacokinetics on the absorption of glycyrrhizic acid (GA). Due to the unique properties of indirect competitive enzyme-linked immunos... |
PMC8855821 | core_pubmed_pmc | Pharmacokinetics of high-titer anti–SARS-CoV-2 human convalescent plasma in high-risk children | Pharmacokinetics of high-titer anti–SARS-CoV-2 human convalescent plasma in high-risk children Abstract Abstract BACKGROUND While most children who contract COVID-19 experience mild disease, high-risk children with underlying conditions may develop severe disease, requiring interventions. Kinetics of antibodies transfe... |
PMC8891816 | core_pubmed_pmc | miR-221/222 as biomarkers and targets for therapeutic intervention on cancer and other diseases: A systematic review | miR-221/222 as biomarkers and targets for therapeutic intervention on cancer and other diseases: A systematic review Abstract Abstract Among deregulated microRNAs (miRs) in human malignancies, miR-221 has been widely investigated for its oncogenic role and as a promising biomarker. Moreover, recent evidence suggests mi... |
PMC6734012 | core_pubmed_pmc | In vivo evaluation of safety, biodistribution and pharmacokinetics of laser-synthesized gold nanoparticles | In vivo evaluation of safety, biodistribution and pharmacokinetics of laser-synthesized gold nanoparticles Abstract Abstract Capable of generating plasmonic and other effects, gold nanostructures can offer a variety of diagnostic and therapy functionalities for biomedical applications, but conventional chemically-synth... |
PMC8518962 | core_pubmed_pmc | Rational dosage regimens for cephalothin and cefazolin using pharmacokinetics and pharmacodynamics analysis in healthy horses | Rational dosage regimens for cephalothin and cefazolin using pharmacokinetics and pharmacodynamics analysis in healthy horses Abstract Abstract Background First‐generation cephalosporins have good activity against gram‐positive bacteria and are extensively used in horses. There are few reports of pharmacokinetics and p... |
PMC11047434 | core_pubmed_pmc | Comparative Pharmacokinetics of Gentamicin C 1 , C 1a and C 2 in Healthy and Infected Piglets | Comparative Pharmacokinetics of Gentamicin C 1 , C 1a and C 2 in Healthy and Infected Piglets Abstract Gentamicin, an aminoglycoside antibiotic, is a mixture of therapeutically active C 1 , C 1a , C 2 and other minor components. Despite its decades-long use in pigs and other species, its intramuscular (IM) pharmacokine... |
PMC8130760 | core_pubmed_pmc | NKTR-255, a novel polymer-conjugated rhIL-15 with potent antitumor efficacy | NKTR-255, a novel polymer-conjugated rhIL-15 with potent antitumor efficacy Abstract Abstract Background NKTR-255 is a novel polyethylene glycol-conjugate of recombinant human interleukin-15 (rhIL-15), which was designed to retain all known receptor binding interactions of the IL-15 molecule. We explored the biologic a... |
PMC10681534 | core_pubmed_pmc | Killing a fly with a sledgehammer: Atezolizumab exposure in real‐world lung cancer patients | Killing a fly with a sledgehammer: Atezolizumab exposure in real‐world lung cancer patients Abstract Abstract Atezolizumab is an anti‐PDL1 approved for treating lung cancer. A threshold of 6 μg/mL in plasma has been associated with target engagement. The extent to which patients could be overexposed with the standard 1... |
PMC11995945 | core_pubmed_pmc | Research Progress of Hydromorphone in Clinical Application | Research Progress of Hydromorphone in Clinical Application Abstract Summary A common opioid analgesic for cancer pain and, to a lesser extent, non-cancer pain, is hydromorphone (HM). Oral formulations as well as subcutaneous, intravenous, and other routes are frequently used for its administration. Its pharmacokinetics... |
PMC9082346 | core_pubmed_pmc | Pre-clinical pharmacokinetic-pharmacodynamic modelling and biodistribution studies of donepezil hydrochloride by a validated HPLC method † | Pre-clinical pharmacokinetic-pharmacodynamic modelling and biodistribution studies of donepezil hydrochloride by a validated HPLC method † Abstract Abstract A simple, sensitive and robust HPLC–PDA assay was developed and validated for rapid determination of donepezil hydrochloride (DNP), a potent acetylcholinesterase i... |
PMC10142912 | core_pubmed_pmc | Pharmacokinetics and Pharmacodynamics of Antibody-Drug Conjugates Administered via Subcutaneous and Intratumoral Routes | Pharmacokinetics and Pharmacodynamics of Antibody-Drug Conjugates Administered via Subcutaneous and Intratumoral Routes Abstract Abstract We hypothesize that different routes of administration may lead to altered pharmacokinetics/pharmacodynamics (PK/PD) behavior of antibody-drug conjugates (ADCs) and may help to impro... |
PMC10295034 | core_pubmed_pmc | Gabapentin: Clinical Use and Pharmacokinetics in Dogs, Cats, and Horses | Gabapentin: Clinical Use and Pharmacokinetics in Dogs, Cats, and Horses Abstract Abstract Simple Summary Gabapentin is an anticonvulsant drug effective in humans to control neuropathic pain. In veterinary medicine, is extra-label used in combination with other treatments to control seizures when other drugs are not eff... |
PMC4878668 | core_pubmed_pmc | Critical evaluation of ceftolozane–tazobactam for complicated urinary tract and intra-abdominal infections | Critical evaluation of ceftolozane–tazobactam for complicated urinary tract and intra-abdominal infections Abstract Abstract The rise in resistant Gram-negative pathogens continues to challenge clinicians treating infections. These resistant infections have inspired the development of new antimicrobial agents, includin... |
PMC10149208 | core_pubmed_pmc | A validated HPLC-MS/MS method for simultaneously analyzing curcumin, demethoxycurcumin, bisdemethoxycurcumin, tetra-hydrocurcumin and piperine in human plasma, urine or feces | A validated HPLC-MS/MS method for simultaneously analyzing curcumin, demethoxycurcumin, bisdemethoxycurcumin, tetra-hydrocurcumin and piperine in human plasma, urine or feces Abstract Abstract Background The spice curcumin is supposed to have many different beneficial health effects. To understand the complete pharmaco... |
PMC10982467 | core_pubmed_pmc | Application of machine learning combined with population pharmacokinetics to improve individual prediction of vancomycin clearance in simulated adult patients | Application of machine learning combined with population pharmacokinetics to improve individual prediction of vancomycin clearance in simulated adult patients Abstract Abstract Background and aim: Vancomycin, a glycopeptide antimicrobial drug. PPK has problems such as difficulty in accurately reflecting inter-individua... |
PMC12057341 | core_pubmed_pmc | In vitro pharmacokinetic/pharmacodynamic modeling of the effect of mucin on polymyxin B activity against Acinetobacter baumannii | In vitro pharmacokinetic/pharmacodynamic modeling of the effect of mucin on polymyxin B activity against Acinetobacter baumannii Abstract ABSTRACT The antibacterial efficacy of polymyxins in lungs may be impacted by mucin. The aim of this study was to characterize in vitro the effect of mucin on polymyxin B (PMB) activ... |
PMC9728921 | core_pubmed_pmc | Characterization of a KDM5 small molecule inhibitor with antiviral activity against hepatitis B virus | Characterization of a KDM5 small molecule inhibitor with antiviral activity against hepatitis B virus Abstract Abstract Chronic hepatitis B (CHB) is a global health care challenge and a major cause of liver disease. To find new therapeutic avenues with a potential to functionally cure chronic Hepatitis B virus (HBV) in... |
PMC4133207 | core_pubmed_pmc | Effects of Aprepitant on the Pharmacokinetics of Controlled-Release Oral Oxycodone in Cancer Patients | Effects of Aprepitant on the Pharmacokinetics of Controlled-Release Oral Oxycodone in Cancer Patients Abstract Abstract Purpose Oxycodone is a µ-opioid receptor agonist widely used in the treatment of cancer pain. The predominant metabolic pathway of oxycodone is CYP3A4-mediated N-demethylation to noroxycodone, while a... |
PMC7984390 | core_pubmed_pmc | Tucatinib Inhibits Renal Transporters OCT2 and MATE Without Impacting Renal Function in Healthy Subjects | Tucatinib Inhibits Renal Transporters OCT2 and MATE Without Impacting Renal Function in Healthy Subjects Abstract Abstract Tucatinib is a potent tyrosine kinase inhibitor selective for human epidermal growth factor receptor 2 (HER2) approved by the US Food and Drug Administration for the treatment of HER2‐positive meta... |
PMC12070030 | core_pubmed_pmc | Safety, Pharmacokinetics, and Pharmacodynamics of a 6‐h N , N ‐Dimethyltryptamine (DMT) Infusion in Healthy Volunteers: A Randomized, Double‐Blind, Placebo‐Controlled Trial | Safety, Pharmacokinetics, and Pharmacodynamics of a 6‐h N , N ‐Dimethyltryptamine (DMT) Infusion in Healthy Volunteers: A Randomized, Double‐Blind, Placebo‐Controlled Trial Abstract ABSTRACT The serotonergic psychedelic N , N ‐dimethyltryptamine (DMT) presumably stimulates neuroplasticity in vitro and in vivo, by which... |
PMC9985638 | core_pubmed_pmc | Fate of arsenicals in mice carrying the human AS3MT gene exposed to environmentally relevant levels of arsenite in drinking water | Fate of arsenicals in mice carrying the human AS3MT gene exposed to environmentally relevant levels of arsenite in drinking water Abstract Abstract Although mice are widely used to study adverse effects of inorganic arsenic (iAs), higher rates of iAs methylation in mice than in humans may limit their utility as a model... |
PMC6651405 | core_pubmed_pmc | Cardiodynamic Interactions between Two S1P 1 Receptor Modulators in an Experimental Clinical Setting: Different Pharmacokinetic Properties as an Opportunity to Mitigate First-Dose Heart Rate Effects | Cardiodynamic Interactions between Two S1P 1 Receptor Modulators in an Experimental Clinical Setting: Different Pharmacokinetic Properties as an Opportunity to Mitigate First-Dose Heart Rate Effects Abstract A decrease in heart rate (HR) is a well-established first-dose effect of sphingosine-1-phosphate subtype 1 recep... |
PMC8001274 | core_pubmed_pmc | Impact on Antibiotic Resistance, Therapeutic Success, and Control of Side Effects in Therapeutic Drug Monitoring (TDM) of Daptomycin: A Scoping Review | Impact on Antibiotic Resistance, Therapeutic Success, and Control of Side Effects in Therapeutic Drug Monitoring (TDM) of Daptomycin: A Scoping Review Abstract Antimicrobial resistance (AR) is a problem that threatens the search for adequate safe and effective antibiotic therapy against multi-resistant bacteria like me... |
PMC9459017 | core_pubmed_pmc | Pharmacokinetic and pharmacodynamic similarity evaluation between an insulin glargine biosimilar product and Lantus ® in healthy subjects: Pharmacokinetic parameters of both parent insulin glargine and M1 were used as endpoints | Pharmacokinetic and pharmacodynamic similarity evaluation between an insulin glargine biosimilar product and Lantus ® in healthy subjects: Pharmacokinetic parameters of both parent insulin glargine and M1 were used as endpoints Abstract Abstract Insulin glargine is a long-acting insulin analog, which plays an important... |
PMC5284489 | core_pubmed_pmc | Oral administration of γ-glutamylcysteine increases intracellular glutathione levels above homeostasis in a randomised human trial pilot study ☆ | Oral administration of γ-glutamylcysteine increases intracellular glutathione levels above homeostasis in a randomised human trial pilot study ☆ Abstract Abstract Objective To determine if orally dosed γ-glutamylcysteine (γ-GC) can increase cellular glutathione (GSH) levels above homeostasis. Many chronic and age-relat... |
PMC12916302 | core_pubmed_pmc | Resolving DNA origami structural integrity and pharmacokinetics in vivo | Resolving DNA origami structural integrity and pharmacokinetics in vivo Abstract DNA origami holds great potential for advancing therapeutics, but the lack of methods for the precise assessment of structural integrity in vivo prevents its translation. Here we introduce proximity ligation assay for structural tracking a... |
PMC4389569 | core_pubmed_pmc | Immunogenicity of Anti-TNF-α Biotherapies: I. Individualized Medicine Based on Immunopharmacological Evidence | Immunogenicity of Anti-TNF-α Biotherapies: I. Individualized Medicine Based on Immunopharmacological Evidence Abstract Abstract Specific inhibition of the cytokine, tumor necrosis factor-α (TNF), has revolutionized the treatment of patients with several autoimmune diseases, and genetically engineered anti-TNF antibody ... |
PMC9686322 | core_pubmed_pmc | The pharmacokinetics of continuous subcutaneous levodopa/carbidopa infusion: Findings from the ND0612 clinical development program | The pharmacokinetics of continuous subcutaneous levodopa/carbidopa infusion: Findings from the ND0612 clinical development program Abstract Abstract Background While treatment with levodopa remains the cornerstone of Parkinson's disease (PD) management, chronic oral therapy is often associated with the development of m... |
PMC6272148 | core_pubmed_pmc | Comparative Pharmacokinetics of Hypaconitine after Oral Administration of Pure Hypaconitine, Aconitum carmichaelii Extract and Sini Decoction to Rats | Comparative Pharmacokinetics of Hypaconitine after Oral Administration of Pure Hypaconitine, Aconitum carmichaelii Extract and Sini Decoction to Rats Abstract Hypaconitine (HC) is one of the main aconitum alkaloids in Aconitum carmichaelii (AC), which is considered to be effective on cardiovascular disease, although it... |
PMC6694038 | core_pubmed_pmc | Pharmacogenomic–pharmacokinetic study of selective estrogen-receptor modulators with intra-patient dose escalation in breast cancer | Pharmacogenomic–pharmacokinetic study of selective estrogen-receptor modulators with intra-patient dose escalation in breast cancer Abstract Background An association between CYP2D6 polymorphisms and tamoxifen (TAM) efficacy has not been confirmed, partly due to unreliable prediction of active metabolite exposure solel... |
PMC5217920 | core_pubmed_pmc | Phase I study of irinotecan for previously treated lung cancer patients with the UGT1A1 * 28 or * 6 polymorphism: R esults of the L ung O ncology G roup in K yushu ( LOGIK 1004 A ) | Phase I study of irinotecan for previously treated lung cancer patients with the UGT1A1 * 28 or * 6 polymorphism: R esults of the L ung O ncology G roup in K yushu ( LOGIK 1004 A ) Abstract Background Various polymorphisms have been detected in the UDP ‐glucuronosyltransferase 1 A ( UGT1A ) gene, and UGT1A1 *28 and UGT... |
PMC7248905 | core_pubmed_pmc | Development of UHPLC-MS/MS Method for Indirubin-3′-Oxime Derivative as a Novel FLT3 Inhibitor and Pharmacokinetic Study in Rats | Development of UHPLC-MS/MS Method for Indirubin-3′-Oxime Derivative as a Novel FLT3 Inhibitor and Pharmacokinetic Study in Rats Abstract This study aimed to develop and validate a sensitive liquid chromatography-coupled tandem mass spectrometry method for the quantification of LDD-2614, an indirubin derivative and nove... |
PMC10363172 | core_pubmed_pmc | Evaluation and comparison of pharmacokinetic profiles and safety of two extended-release buprenorphine formulations in common marmosets ( Callithrix jacchus ) | Evaluation and comparison of pharmacokinetic profiles and safety of two extended-release buprenorphine formulations in common marmosets ( Callithrix jacchus ) Abstract While sustained-release buprenorphine (BSR) is used as a long-lasting opioid analgesic in common marmosets ( Callithrix jacchus ), there are no publishe... |
PMC12196254 | core_pubmed_pmc | Unveiling the Polypharmacological Potency of FDA-Approved Rebamipide for Alzheimer’s Disease | Unveiling the Polypharmacological Potency of FDA-Approved Rebamipide for Alzheimer’s Disease Abstract Background: Alzheimer’s disease (AD) is a multifactorial neurodegenerative disorder characterised by the accumulation of neurotoxic substances in the brain, ultimately leading to progressive cognitive decline. The comp... |
PMC7363839 | core_pubmed_pmc | A Peptide-Based PD1 Antagonist Enhances T-Cell Priming and Efficacy of a Prophylactic Malaria Vaccine and Promotes Survival in a Lethal Malaria Model | A Peptide-Based PD1 Antagonist Enhances T-Cell Priming and Efficacy of a Prophylactic Malaria Vaccine and Promotes Survival in a Lethal Malaria Model Abstract The blockade of programmed cell death-1 (PD1) and its ligand PDL1 has been proven to be a successful immunotherapy against several cancers. Similar to cancer, PD... |
PMC8212746 | core_pubmed_pmc | A target‐mediated drug disposition population pharmacokinetic model of GC1118, a novel anti‐EGFR antibody, in patients with solid tumors | A target‐mediated drug disposition population pharmacokinetic model of GC1118, a novel anti‐EGFR antibody, in patients with solid tumors Abstract Abstract Abstract GC1118 is a monoclonal antibody for epidermal growth factor receptor (EGFR) that is currently under clinical development to treat patients with solid tumors... |
PMC5172513 | core_pubmed_pmc | Plasma Efavirenz Exposure, Sex, and Age Predict Virological Response in HIV-Infected African Children | Plasma Efavirenz Exposure, Sex, and Age Predict Virological Response in HIV-Infected African Children Abstract Supplemental Digital Content is Available in the Text. Key Words: efavirenz, PK/PD, children Abstract Background: Owing to insufficient evidence in children, target plasma concentrations of efavirenz are based... |
PMC7167245 | core_pubmed_pmc | The preclinical pharmacological study on HX0969W, a novel water-soluble pro-drug of propofol, in rats | The preclinical pharmacological study on HX0969W, a novel water-soluble pro-drug of propofol, in rats Abstract Background Propofol is the most widely used intravenous sedative-hypnotic anesthetic in clinical practice. However, many serious side effects have been related to its lipid emulsion formulation. The pro-drug d... |
PMC12649290 | core_pubmed_pmc | Osimertinib Cost Minimization in Non‐Small Cell Lung Cancer (NSCLC) Treatment: Hypothesis Generation for a Population Pharmacokinetic Approach for Equivalent Dose Optimization of Osimertinib in Combination with Cobicistat | Osimertinib Cost Minimization in Non‐Small Cell Lung Cancer (NSCLC) Treatment: Hypothesis Generation for a Population Pharmacokinetic Approach for Equivalent Dose Optimization of Osimertinib in Combination with Cobicistat Abstract Abstract Pharmacokinetic boosting can be a strategy to enhance osimertinib exposure and r... |
PMC10102054 | core_pubmed_pmc | Evidence of trospium’s ability to mitigate cholinergic adverse events related to xanomeline: phase 1 study results | Evidence of trospium’s ability to mitigate cholinergic adverse events related to xanomeline: phase 1 study results Abstract Rationale The M 1 /M 4 preferring muscarinic receptor agonist xanomeline demonstrated antipsychotic and procognitive effects in patients with Alzheimer’s disease or schizophrenia in prior studies,... |
PMC10828974 | core_pubmed_pmc | Safety, pharmacokinetics, and food effect of sudapyridine (WX‐081), a novel anti‐tuberculosis candidate in healthy Chinese subjects | Safety, pharmacokinetics, and food effect of sudapyridine (WX‐081), a novel anti‐tuberculosis candidate in healthy Chinese subjects Abstract Abstract This study aimed to assess the safety, pharmacokinetics, and food impact on sudapyridine (WX‐081), a novel drug designed to inhibit mycobacterium ATP synthase, with clini... |
PMC11765766 | core_pubmed_pmc | Utilization of Cannabidiol in Post-Organ-Transplant Care | Utilization of Cannabidiol in Post-Organ-Transplant Care Abstract Abstract Cannabidiol (CBD) is one of the major phytochemical constituents of cannabis, Cannabis sativa , widely recognized for its therapeutic potential. While cannabis has been utilized for medicinal purposes since ancient times, its psychoactive and ad... |
PMC4394611 | core_pubmed_pmc | Interactive Pharmacometric Applications Using R and the Shiny Package | Interactive Pharmacometric Applications Using R and the Shiny Package Abstract Interactive applications, developed using Shiny for the R programming language, have the potential to revolutionize the sharing and communication of pharmacometric model simulations. Shiny allows customization of the application's user-inter... |
PMC9229376 | core_pubmed_pmc | Drug-Drug Interactions of Direct Oral Anticoagulants (DOACs): From Pharmacological to Clinical Practice | Drug-Drug Interactions of Direct Oral Anticoagulants (DOACs): From Pharmacological to Clinical Practice Abstract Abstract The direct oral anticoagulants (DOACs), dabigatran, rivaroxaban, apixaban, and edoxaban, are becoming the most commonly prescribed drugs for preventing ischemic stroke in patients with non-valvular ... |
PMC12814314 | core_pubmed_pmc | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Doses and Dose Titration of Bexicaserin in Healthy Participants in a Randomized, Double‐Blind, Placebo‐Controlled Study | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Doses and Dose Titration of Bexicaserin in Healthy Participants in a Randomized, Double‐Blind, Placebo‐Controlled Study Abstract Abstract Bexicaserin (LP352) is a selective superagonist of the 5‐hydroxytryptamine 2C (5‐HT 2C ) receptor c... |
PMC11858801 | core_pubmed_pmc | Chemical Analysis of Plasma-Activated Culture Media by Ion Chromatography | Chemical Analysis of Plasma-Activated Culture Media by Ion Chromatography Abstract Background : Currently, the procedures and methods applied in biological and medical fields for the determination of reactive oxygen and nitrogen species (RONS), primarily rely on spectrophotometric techniques, which involve the use of c... |
PMC9545034 | core_pubmed_pmc | Pharmacokinetics of single and repeated oral doses of pregabalin oral solution formulation in cats | Pharmacokinetics of single and repeated oral doses of pregabalin oral solution formulation in cats Abstract Abstract The study was designed to determine the pharmacokinetic profile and bioavailability of a novel pregabalin 50 mg/ml oral solution formulation (Bonqat ® , Orion Corporation Orion Pharma) in 6 healthy labor... |
PMC10180692 | core_pubmed_pmc | Dietary Oncopharmacognosy as a Crosswalk between Precision Oncology and Precision Nutrition | Dietary Oncopharmacognosy as a Crosswalk between Precision Oncology and Precision Nutrition Abstract Abstract While diet and nutrition are modifiable risk factors for many chronic and infectious diseases, their role in cancer prevention and control remains under investigation. The lack of clarity of some diet–cancer re... |
PMC8072905 | core_pubmed_pmc | Pharmacokinetic Model Analysis of Supralingual, Oral and Intravenous Deliveries of Mycophenolic Acid | Pharmacokinetic Model Analysis of Supralingual, Oral and Intravenous Deliveries of Mycophenolic Acid Abstract Abstract Mycophenolic acid (MPA) is commonly used for organ rejection prophylaxis via oral administration in the clinic. Recent studies have shown that MPA also has anticancer activities. To explore new therape... |
PMC11696247 | core_pubmed_pmc | Replacement therapy in pregnant women with von Willebrand disease during delivery: Factor levels and pharmacokinetics | Replacement therapy in pregnant women with von Willebrand disease during delivery: Factor levels and pharmacokinetics Abstract Abstract Limited data are available on VWF activity (VWF:Act) and factor VIII (FVIII:C) levels during delivery after VWF/FVIII concentrate administration in women with von Willebrand disease (V... |
PMC9810385 | core_pubmed_pmc | A multicenter randomized trials to compare the bioequivalence and safety of a generic doxorubicin hydrochloride liposome injection with Caelyx ® in advanced breast cancer | A multicenter randomized trials to compare the bioequivalence and safety of a generic doxorubicin hydrochloride liposome injection with Caelyx ® in advanced breast cancer Abstract Purpose To compare the pharmacokinetic (PK) bioequivalence (BE) and safety of a generic pegylated liposomal doxorubicin (PLD) formulation wi... |
PMC8395466 | core_pubmed_pmc | Pharmacokinetics of Single Domain Antibodies and Conjugated Nanoparticles Using a Hybrid near Infrared Method | Pharmacokinetics of Single Domain Antibodies and Conjugated Nanoparticles Using a Hybrid near Infrared Method Abstract Iron oxide nanoparticles and single domain antibodies from camelids (VHHs) have been increasingly recognized for their potential uses for medical diagnosis and treatment. However, there have been relat... |
PMC11499563 | core_pubmed_pmc | Modeling the Impact of Ensitrelvir on SARS-CoV-2 Dynamics and Its Application for Assessment of Transmission Mitigation of Patients with COVID-19 | Modeling the Impact of Ensitrelvir on SARS-CoV-2 Dynamics and Its Application for Assessment of Transmission Mitigation of Patients with COVID-19 Abstract Introduction Mathematical modeling can provide quantitative understanding of the viral dynamics and viral reduction effects of drugs and enable simulations of the dy... |
PMC8307883 | core_pubmed_pmc | The Impact of Marijuana on Antidepressant Treatment in Adolescents: Clinical and Pharmacologic Considerations | The Impact of Marijuana on Antidepressant Treatment in Adolescents: Clinical and Pharmacologic Considerations Abstract Abstract The neuropharmacology of marijuana, including its effects on selective serotonin reuptake inhibitor (SSRI)/antidepressant metabolism and the subsequent response and tolerability in youth, has ... |
PMC12405305 | core_pubmed_pmc | Effects of Liver Surgery on Drug Transporters in the Liver and Remote Organs | Effects of Liver Surgery on Drug Transporters in the Liver and Remote Organs Abstract Abstract Alterations in drug transporters in acute liver failure and chronic liver diseases, such as cirrhosis, have been reviewed before. However, there is a lack of comprehensive reviews on how liver surgery, including transplantati... |
PMC7736006 | core_pubmed_pmc | Brain Exposure to Piperacillin in Acute Hemorrhagic Stroke Patients Assessed by Cerebral Microdialysis and Population Pharmacokinetics | Brain Exposure to Piperacillin in Acute Hemorrhagic Stroke Patients Assessed by Cerebral Microdialysis and Population Pharmacokinetics Abstract Background The broad antibacterial spectrum of piperacillin/tazobactam makes the combination suitable for the treatment of nosocomial bacterial central nervous system (CNS) inf... |
PMC7659583 | core_pubmed_pmc | AKR-001, an Fc-FGF21 Analog, Showed Sustained Pharmacodynamic Effects on Insulin Sensitivity and Lipid Metabolism in Type 2 Diabetes Patients | AKR-001, an Fc-FGF21 Analog, Showed Sustained Pharmacodynamic Effects on Insulin Sensitivity and Lipid Metabolism in Type 2 Diabetes Patients Abstract Summary Experimental fibroblast growth factor 21 (FGF21) analogs can improve lipid profiles in patients with metabolic diseases. However, their effects on markers of ins... |
PMC9787578 | core_pubmed_pmc | Possible Mechanisms of the Interplay between Drugs and Mycotoxins—Is There a Possible Impact? | Possible Mechanisms of the Interplay between Drugs and Mycotoxins—Is There a Possible Impact? Abstract Mycotoxin contamination is a global food safety issue leading to major public health concerns. Repeated exposure to multiple mycotoxins not only has repercussions on human health but could theoretically also lead to i... |
PMC6669291 | core_pubmed_pmc | Microbiology and Preclinical Review of Omadacycline | Microbiology and Preclinical Review of Omadacycline Abstract Abstract Omadacycline is a novel aminomethylcycline antimicrobial and semisynthetic derivative of tetracycline. In vitro, omadacycline displays potent activity against gram-positive and many gram-negative bacteria, including methicillin-resistant Staphylococc... |
PMC5567880 | core_pubmed_pmc | Hypoglycemia Risk Related to Double Dose Is Markedly Reduced with Basal Insulin Peglispro Versus Insulin Glargine in Patients with Type 2 Diabetes Mellitus in a Randomized Trial: IMAGINE 8 | Hypoglycemia Risk Related to Double Dose Is Markedly Reduced with Basal Insulin Peglispro Versus Insulin Glargine in Patients with Type 2 Diabetes Mellitus in a Randomized Trial: IMAGINE 8 Abstract Abstract Background: Basal insulin peglispro (BIL) has a peripheral-to-hepatic distribution of action that resembles endog... |
PMC3161942 | core_pubmed_pmc | An evaluation of ciprofloxacin pharmacokinetics in critically ill patients undergoing continuous veno-venous haemodiafiltration | An evaluation of ciprofloxacin pharmacokinetics in critically ill patients undergoing continuous veno-venous haemodiafiltration Abstract Background The study aimed to investigate the pharmacokinetics of intravenous ciprofloxacin and the adequacy of 400 mg every 12 hours in critically ill Intensive Care Unit (ICU) patie... |
PMC7243359 | core_pubmed_pmc | Right Dose, Right Now: Development of AutoKinetics for Real Time Model Informed Precision Antibiotic Dosing Decision Support at the Bedside of Critically Ill Patients | Right Dose, Right Now: Development of AutoKinetics for Real Time Model Informed Precision Antibiotic Dosing Decision Support at the Bedside of Critically Ill Patients Abstract Introduction Antibiotic dosing in critically ill patients is challenging because their pharmacokinetics (PK) are altered and may change rapidly ... |
PMC11249631 | core_pubmed_pmc | Nitric Oxide Donor Sodium Nitroprusside Reduces Racemic Ketamine—But Not Esketamine-Induced Pain Relief | Nitric Oxide Donor Sodium Nitroprusside Reduces Racemic Ketamine—But Not Esketamine-Induced Pain Relief Abstract The anesthetic, analgesic and antidepressant drug ketamine produces dissociation with symptoms of psychosis and anxiety, an effect attributed to neuronal nitric oxide depletion following N -methyl- d -aspart... |
PMC9324692 | core_pubmed_pmc | Glucose-Modified Zein Nanoparticles Enhance Oral Delivery of Docetaxel | Glucose-Modified Zein Nanoparticles Enhance Oral Delivery of Docetaxel Abstract Abstract Based on glucose (G) transporters (GLUTs), structuring nanoparticles with G as a target are an effective strategy to enhance oral bioavailability and anti-tumor effects of drugs. A novel drug delivery system using G-modified zein (... |
PMC10099566 | core_pubmed_pmc | Pharmacokinetics of a single dose of Aficamten (CK‐274) on cardiac contractility in a A31P MYBPC3 hypertrophic cardiomyopathy cat model | Pharmacokinetics of a single dose of Aficamten (CK‐274) on cardiac contractility in a A31P MYBPC3 hypertrophic cardiomyopathy cat model Abstract Abstract Hypertrophic cardiomyopathy (HCM) is the most prevalent cardiac disease in cats and lacks efficacious preclinical pharmacologic intervention, prompting investigation ... |
PMC8020363 | core_pubmed_pmc | Pharmacokinetic comparison between a fixed-dose combination of fimasartan/amlodipine/hydrochlorothiazide 60/10/25 mg and a corresponding loose combination of fimasartan/amlodipine 60/25 mg and hydrochlorothiazide 25 mg in healthy subjects | Pharmacokinetic comparison between a fixed-dose combination of fimasartan/amlodipine/hydrochlorothiazide 60/10/25 mg and a corresponding loose combination of fimasartan/amlodipine 60/25 mg and hydrochlorothiazide 25 mg in healthy subjects Abstract For the treatment of hypertension, fixed-dose combinations (FDCs) of ant... |
PMC4478171 | core_pubmed_pmc | Synthesis, characterization, and preclinical validation of a PET radiopharmaceutical for interrogating Aβ (β-amyloid) plaques in Alzheimer’s disease | Synthesis, characterization, and preclinical validation of a PET radiopharmaceutical for interrogating Aβ (β-amyloid) plaques in Alzheimer’s disease Abstract Background PET radiopharmaceuticals capable of imaging β-amyloid (Aβ) plaque burden in the brain could offer highly valuable diagnostic tools for clinical studies... |
PMC6496160 | core_pubmed_pmc | Software for Dosage Individualization of Voriconazole: a Prospective Clinical Study | Software for Dosage Individualization of Voriconazole: a Prospective Clinical Study Abstract Voriconazole is a first-line antifungal agent. Therapeutic drug monitoring is a standard of care. ABSTRACT Voriconazole is a first-line antifungal agent. Therapeutic drug monitoring is a standard of care. The best way to adjust... |
PMC4529098 | core_pubmed_pmc | First-In-Human, Phase 1, Randomized, Dose-Escalation Trial with Recombinant Anti–IL-20 Monoclonal Antibody in Patients with Psoriasis | First-In-Human, Phase 1, Randomized, Dose-Escalation Trial with Recombinant Anti–IL-20 Monoclonal Antibody in Patients with Psoriasis Abstract Abstract Background The current trial was a first-in-human clinical trial evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of th... |
PMC3543549 | core_pubmed_pmc | The incidence and clinical relevance of drug interactions in pediatrics | The incidence and clinical relevance of drug interactions in pediatrics Abstract Abstract Objective: To investigate the prevalence of the major drug interactions in children and verify the rate and profile of drug interactions in hospitalized pediatric patients. Materials and Methods: A retrospective study was designed... |
PMC9007599 | core_pubmed_pmc | Streamlining physiologically‐based pharmacokinetic model design for intravenous delivery of nanoparticle drugs | Streamlining physiologically‐based pharmacokinetic model design for intravenous delivery of nanoparticle drugs Abstract Abstract Physiologically‐based pharmacokinetic (PBPK) modeling for nanoparticles elucidates the nanoparticle drug’s disposition in the body and serves a vital role in drug development and clinical stu... |
PMC5529739 | core_pubmed_pmc | Population Modeling of Selexipag Pharmacokinetics and Clinical Response Parameters in Patients With Pulmonary Arterial Hypertension | Population Modeling of Selexipag Pharmacokinetics and Clinical Response Parameters in Patients With Pulmonary Arterial Hypertension Abstract Selexipag (Uptravi) is an oral selective IP prostacyclin receptor agonist approved for the treatment of pulmonary arterial hypertension (PAH). The pivotal GRIPHON study was the la... |
PMC10787214 | core_pubmed_pmc | A tutorial for model‐based evaluation and translation of cardiovascular safety in preclinical trials | A tutorial for model‐based evaluation and translation of cardiovascular safety in preclinical trials Abstract Abstract Assessment of drug‐induced effects on the cardiovascular (CV) system remains a critical component of the drug discovery process enabling refinement of the therapeutic index. Predicting potential drug‐r... |
PMC10277268 | core_pubmed_pmc | Pharmacokinetic analysis of vilobelimab, anaphylatoxin C5a and antidrug antibodies in PANAMO: a phase 3 study in critically ill, invasively mechanically ventilated COVID-19 patients | Pharmacokinetic analysis of vilobelimab, anaphylatoxin C5a and antidrug antibodies in PANAMO: a phase 3 study in critically ill, invasively mechanically ventilated COVID-19 patients Abstract Background Vilobelimab, a complement 5a (C5a)-specific monoclonal antibody, reduced mortality in critically ill COVID-19 patients... |
PMC5533838 | core_pubmed_pmc | Pharmacokinetic-Pharmacodynamic Relationship of Erenumab (AMG 334) and Capsaicin-Induced Dermal Blood Flow in Healthy and Migraine Subjects | Pharmacokinetic-Pharmacodynamic Relationship of Erenumab (AMG 334) and Capsaicin-Induced Dermal Blood Flow in Healthy and Migraine Subjects Abstract Abstract Purpose Capsaicin-induced dermal blood flow (CIDBF) is a validated biomarker used to evaluate the target engagement of potential calcitonin gene-related peptide-b... |
PMC8478527 | core_pubmed_pmc | Application of Auxiliary VerifyNow Point-of-Care Assays to Assess the Pharmacodynamics of RUC-4, a Novel αIIbβ3 Receptor Antagonist | Application of Auxiliary VerifyNow Point-of-Care Assays to Assess the Pharmacodynamics of RUC-4, a Novel αIIbβ3 Receptor Antagonist Abstract Introduction Prehospital therapy of ST-elevation myocardial infarction (STEMI) with αIIbβ3 antagonists improves clinical outcomes, but they are difficult to use in prehospital set... |
PMC6095934 | core_pubmed_pmc | Impact of rifampicin-inhibitable transport on the liver distribution and tissue kinetics of erlotinib assessed with PET imaging in rats | Impact of rifampicin-inhibitable transport on the liver distribution and tissue kinetics of erlotinib assessed with PET imaging in rats Abstract Background Erlotinib is an epidermal growth factor receptor (EGFR)-targeting tyrosine kinase inhibitor approved for treatment of non-small cell lung cancer. The wide inter-ind... |
PMC12115528 | core_pubmed_pmc | The Suitability of Dried Blood Spot Sampling for Pharmacokinetic Studies in Veterinary Medicine | The Suitability of Dried Blood Spot Sampling for Pharmacokinetic Studies in Veterinary Medicine Abstract Simple Summary Dried blood spot (DBS) sampling is a microsampling technique that involves collecting small volumes of blood on absorbent paper for later analysis. It offers several advantages, including minimal inva... |
PMC12486832 | core_pubmed_pmc | Evaluation of cycloserine dose regimens in an Indian cohort with multidrug-resistant tuberculosis: a population pharmacokinetic analysis | Evaluation of cycloserine dose regimens in an Indian cohort with multidrug-resistant tuberculosis: a population pharmacokinetic analysis Abstract ABSTRACT Cycloserine is recommended for inclusion in regimens for multidrug-resistant tuberculosis (MDR-TB). Its efficacy is time dependent and relies on the concentration re... |
PMC11731318 | core_pubmed_pmc | Drug Interaction Studies of Cabamiquine:Ganaplacide Combination against Hepatic Plasmodium berghei | Drug Interaction Studies of Cabamiquine:Ganaplacide Combination against Hepatic Plasmodium berghei Abstract New antimalarial combination therapies with novel modes of action are required to counter the emergence and spread of Plasmodium drug resistance against existing therapeutics. Here, we present a study to evaluate... |
PMC5376394 | core_pubmed_pmc | A whole-body physiologically based pharmacokinetic (WB-PBPK) model of ciprofloxacin: a step towards predicting bacterial killing at sites of infection | A whole-body physiologically based pharmacokinetic (WB-PBPK) model of ciprofloxacin: a step towards predicting bacterial killing at sites of infection Abstract Abstract The purpose of this study was to develop a whole-body physiologically based pharmacokinetic (WB-PBPK) model for ciprofloxacin for ICU patients, based o... |
PMC4706177 | core_pubmed_pmc | A Lanthanum-Tagged Chemotherapeutic Agent HA-Pt to Track the In Vivo Distribution of Hyaluronic Acid Complexes | A Lanthanum-Tagged Chemotherapeutic Agent HA-Pt to Track the In Vivo Distribution of Hyaluronic Acid Complexes Abstract Hyaluronic acid drug conjugates can target anti-cancer drugs directly to tumor tissue for loco-regional treatment with enhanced bioavailability, local efficacy and reduced toxicity. In this study, the... |
PMC3135225 | core_pubmed_pmc | Cardiovascular Side Effects of Atomoxetine and Its Interactions with Inhibitors of the Cytochrome P450 System | Cardiovascular Side Effects of Atomoxetine and Its Interactions with Inhibitors of the Cytochrome P450 System Abstract Attention deficit hyperactivity disorder (ADHD) is one of the most common neurobehavioral disorders of childhood and adolescence. Classically, stimulants have been used in the treatment of this conditi... |
PMC6813168 | core_pubmed_pmc | A Physiologically‐Based Pharmacokinetic Model for the Prediction of Monoclonal Antibody Pharmacokinetics From In Vitro Data | A Physiologically‐Based Pharmacokinetic Model for the Prediction of Monoclonal Antibody Pharmacokinetics From In Vitro Data Abstract Abstract Monoclonal antibody (mAb) pharmacokinetics (PK) have largely been predicted via allometric scaling with little consideration for cross‐species differences in neonatal Fc receptor... |
PMC11144404 | core_pubmed_pmc | Evaluation of Drug-Drug Interaction Between Henagliflozin and Hydrochlorothiazide in Healthy Chinese Volunteers | Evaluation of Drug-Drug Interaction Between Henagliflozin and Hydrochlorothiazide in Healthy Chinese Volunteers Abstract Purpose Henagliflozin is an original, selective sodium-glucose cotransporter 2 (SGLT2) inhibitor. Hydrochlorothiazide (HCTZ) is a common anti-hypertensive drug. This study aimed to evaluate the poten... |
PMC6813166 | core_pubmed_pmc | Population Pharmacokinetic Analysis for Imipenem–Relebactam in Healthy Volunteers and Patients With Bacterial Infections | Population Pharmacokinetic Analysis for Imipenem–Relebactam in Healthy Volunteers and Patients With Bacterial Infections Abstract Relebactam is a small‐molecule β‐lactamase inhibitor developed as a fixed‐dose combination with imipenem/cilastatin. The pharmacokinetics of relebactam and imipenem across 10 clinical studie... |
PMC9332521 | core_pubmed_pmc | Pharmacokinetic interactions of herbal medicines for the treatment of chronic hepatitis | Pharmacokinetic interactions of herbal medicines for the treatment of chronic hepatitis Abstract Chronic liver disease is a serious global health problem, and an increasing number of patients are seeking alternative medicines or complementary treatment. Herbal medicines account for 16.8% of patients with chronic liver ... |
PMC7932937 | core_pubmed_pmc | Pharmacokinetic/Pharmacodynamic Modelling to Describe the Cholesterol Lowering Effect of Rosuvastatin in People Living with HIV | Pharmacokinetic/Pharmacodynamic Modelling to Describe the Cholesterol Lowering Effect of Rosuvastatin in People Living with HIV Abstract Abstract Background Rosuvastatin is a lipid-lowering agent widely prescribed in people living with HIV, which is actively transported into the liver, making it a potential victim of d... |
PMC8300709 | core_pubmed_pmc | Exploration of Clinical Breakpoint of Danofloxacin for Glaesserella parasuis in Plasma and in PELF | Exploration of Clinical Breakpoint of Danofloxacin for Glaesserella parasuis in Plasma and in PELF Abstract Abstract Background: In order to establish the clinical breakpoint (CBP) of danofloxacin against G. parasuis , three cutoff values, including epidemiological cutoff value (ECV), pharmacokinetic-pharmacodynamic (P... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.